WEBULL
WebtradeDownload

Solventum (SOLV) Wins FDA Clearance, Is The Stock Still A Bargain?

Simply Wall St · 2d ago

Solventum (SOLV) just received FDA 510(k) clearance to market Restrata Matrix together with its V.A.C. Therapy system, a step that formalizes an integrated approach to advanced wound care following the Acera Surgical acquisition.

Set against that regulatory win, Solventum’s recent trading has been steady rather than explosive. The share price stands at US$87.45 after a 1-day share price return of 0.90% and a 90-day share price return of 12.10%, which broadly lines up with a 1-year total shareholder return of 21.00%. This suggests momentum has been gradually building as the market absorbs the Acera Surgical acquisition and this latest FDA clearance.

Compare Solventum's wound care momentum with other health-focused opportunities by scanning our hand-picked 36 healthcare AI stocks that are pushing the edge of medical technology and data-led treatment.

After that measured rerating and fresh FDA clearance, the real puzzle is whether Solventum’s current price still leaves enough upside to justify the risks. Time to weigh what the valuation actually implies.

Most Popular Narrative: 6% Undervalued

Solventum’s most followed valuation framework puts fair value at $93.15, modestly above the latest $87.45 close. This suggests a story of gradual rerating rather than a binary mispricing.

The company's new product innovation pipeline (notably in Negative Pressure Wound Therapy, advanced wound care, sterilization, and digital health solutions such as autonomous coding) is gaining traction, positioning Solventum to benefit from rising global demand for technologically advanced healthcare equipment, ultimately supporting future topline and earnings growth.

See why 34 investors see Solventum as 6% undervalued.

Result: Fair Value of $93.15 (UNDERVALUED)

Still, the Solventum story can change quickly if the 3M separation and ERP rollout hit snags, or if AI pressure weighs on high margin software earnings.

Find out about the key risks to this Solventum narrative.

Next Steps

If this mix of optimism and caution around Solventum feels evenly balanced, consider acting while the information is fresh and weigh both sides for yourself using 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Solventum?

If Solventum has your attention, do not stop here. Broaden your watchlist with fresh, data driven ideas that could sharpen your overall portfolio.